492 related articles for article (PubMed ID: 15047917)
21. Benefit with aromatase inhibitors in the adjuvant setting for postmenopausal women with breast cancer.
Mouridsen HT; Robert NJ
MedGenMed; 2005 Aug; 7(3):20. PubMed ID: 16369246
[TBL] [Abstract][Full Text] [Related]
22. Use of aromatase inhibitors in breast carcinoma.
Santen RJ; Harvey HA
Endocr Relat Cancer; 1999 Mar; 6(1):75-92. PubMed ID: 10732791
[TBL] [Abstract][Full Text] [Related]
23. [Optimal adjuvant hormone therapy in postmenopausal women with hormone-sensitive mammary carcinoma: tamoxifen and the aromatase inhibitors anastrozole, exemestane and letrozole].
van Nes JG; Seynaeve C; van de Velde CJ; Nortier JW
Ned Tijdschr Geneeskd; 2006 Dec; 150(52):2863-9. PubMed ID: 17319217
[TBL] [Abstract][Full Text] [Related]
24. The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
Morandi P; Rouzier R; Altundag K; Buzdar AU; Theriault RL; Hortobagyi G
Cancer; 2004 Oct; 101(7):1482-9. PubMed ID: 15378476
[TBL] [Abstract][Full Text] [Related]
25. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate.
Buzdar A; Douma J; Davidson N; Elledge R; Morgan M; Smith R; Porter L; Nabholtz J; Xiang X; Brady C
J Clin Oncol; 2001 Jul; 19(14):3357-66. PubMed ID: 11454883
[TBL] [Abstract][Full Text] [Related]
26. Aromatase inhibitors for therapy of advanced breast cancer.
Ingle JN; Suman VJ
J Steroid Biochem Mol Biol; 2005 May; 95(1-5):113-9. PubMed ID: 15939585
[TBL] [Abstract][Full Text] [Related]
27. Risks and benefits of aromatase inhibitors in postmenopausal breast cancer.
Michaud LB; Buzdar AU
Drug Saf; 1999 Oct; 21(4):297-309. PubMed ID: 10514021
[TBL] [Abstract][Full Text] [Related]
28. Adjuvant aromatase inhibitor therapy for early breast cancer: A review of the most recent data.
Grana G
J Surg Oncol; 2006 Jun; 93(7):585-92. PubMed ID: 16705732
[TBL] [Abstract][Full Text] [Related]
29. Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer.
Bertelli G; Garrone O; Merlano M; Occelli M; Bertolotti L; Castiglione F; Pepi F; Fusco O; Del Mastro L; Leonard RC
Oncology; 2005; 69(6):471-7. PubMed ID: 16410685
[TBL] [Abstract][Full Text] [Related]
30. Exemestane: a review of its use in postmenopausal women with advanced breast cancer.
Clemett D; Lamb HM
Drugs; 2000 Jun; 59(6):1279-96. PubMed ID: 10882163
[TBL] [Abstract][Full Text] [Related]
31. Prevention strategies with aromatase inhibitors.
Goss PE; Strasser-Weippl K
Clin Cancer Res; 2004 Jan; 10(1 Pt 2):372S-9S. PubMed ID: 14734494
[TBL] [Abstract][Full Text] [Related]
32. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.
Buzdar A; Jonat W; Howell A; Jones SE; Blomqvist C; Vogel CL; Eiermann W; Wolter JM; Azab M; Webster A; Plourde PV
J Clin Oncol; 1996 Jul; 14(7):2000-11. PubMed ID: 8683230
[TBL] [Abstract][Full Text] [Related]
33. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group.
Buzdar AU; Jones SE; Vogel CL; Wolter J; Plourde P; Webster A
Cancer; 1997 Feb; 79(4):730-9. PubMed ID: 9024711
[TBL] [Abstract][Full Text] [Related]
34. The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer.
Hamilton A; Piccart M
Ann Oncol; 1999 Apr; 10(4):377-84. PubMed ID: 10370778
[TBL] [Abstract][Full Text] [Related]
35. Emerging role of aromatase inhibitors in the treatment of breast cancer.
Harvey HA
Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):32-5. PubMed ID: 9556789
[TBL] [Abstract][Full Text] [Related]
36. An overview of the use of non-steroidal aromatase inhibitors in the treatment of breast cancer.
Buzdar A
Eur J Cancer; 2000 Sep; 36 Suppl 4():S82-4. PubMed ID: 11056331
[TBL] [Abstract][Full Text] [Related]
37. Aromatase inhibition in the treatment of advanced breast cancer: is there a relationship between potency and clinical efficacy?
Sainsbury R
Br J Cancer; 2004 May; 90(9):1733-9. PubMed ID: 15150604
[TBL] [Abstract][Full Text] [Related]
38. Aromatase inhibitors in advanced breast cancer.
Mouridsen HT
Semin Oncol; 2004 Dec; 31(6 Suppl 12):3-8. PubMed ID: 15719595
[TBL] [Abstract][Full Text] [Related]
39. Applicability of the intratumor aromatase preclinical model to predict clinical trial results with endocrine therapy.
Brodie AH; Mouridsen HT
Am J Clin Oncol; 2003 Aug; 26(4):S17-26. PubMed ID: 12902873
[TBL] [Abstract][Full Text] [Related]
40. Lessons from the use of aromatase inhibitors in the neoadjuvant setting.
Dixon JM; Love CD; Renshaw L; Bellamy C; Cameron DA; Miller WR; Leonard RC
Endocr Relat Cancer; 1999 Jun; 6(2):227-30. PubMed ID: 10731113
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]